SHRX Sharp Therapeutics Corp.

0.9577USD1.370 CAD · TSXV0.00%Mkt Cap: 28.80M USDP/E: —

Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creat…

Key Statistics

Company
Market Cap28.80M USD
Enterprise Value31.74M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-6.17M USD
Revenue/Share—
Last Price0.9577 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-8.14
EV/Revenue—
P/S—
P/B-13.36
EPS (TTM)-0.28 USD
EPS (Forward)—
52W Range
0.636115% of range2.761
52W High2.761 USD
52W Low0.6361 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE3496.15%
ROA-316.31%
ROIC-2916.24%
ROCE-552.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.83M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-7.96%
Net Debt2.15M USD
Net Debt/EBITDA-0.39
Net Debt/FCF—
Balance Sheet
Debt/Equity-7.26
Current Ratio0.07
Quick Ratio0.05
Book Value/Sh-0.10 USD
Cash/Share0.0030 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJan 27, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.30.08M
Float17.62M
Insiders42.49%
Institutions0.00%
Short Interest
Short Ratio9.9d
Short % Out.0.00%
Shares Short89
Short (prev mo.)89
Technical
SMA 500.9577 (+0.0%)
SMA 2001.121 (-14.6%)
Beta-1.11
S&P 52W Chg12.00%
Avg Vol (30d)0
Avg Vol (10d)0
Technical Indicators
RSI (14)95.5
MACD0.0086
MACD Signal0.0125
MACD Hist.-0.0039
BB Upper0.9577 USD
BB Middle0.9577 USD
BB Lower0.9577 USD
BB Width0.00%
ATR (14)0.0006 USD
Vol Ratio (20d)—

About Sharp Therapeutics (CVE: SHRX)

›

Sharp Therapeutics (CVE: SHRX) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 1.370 CAD on 18 November 2026, down 67.4% over 52 weeks. Its 52-week range is 0.9100 CAD to 3.950 CAD: the price is 65.3% below the high and 50.5% above the low.

Its market capitalisation is 41.20M CAD.

Sharp Therapeutics reports an operating margin of 0.0%.

Its debt exceeds its cash by 2.15M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 26 November 2026.